Residual Tumour Resection Following Inductive Chemotherapy in Advanced Testicular Cancer

European Urology

Volumn 51, Issue 2, 2007, Pages 299-301

  Heidenreich, Axel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EDITORIAL; FIBROSIS; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; TREATMENT OUTCOME; TUMOR NECROSIS;

DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM, RESIDUAL; TESTICULAR NEOPLASMS;

EID: 33845593359     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.06.046     Document Type: Editorial

References (11)

1. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
2. Albers P., Melchior D., and Müller S.C. Surgery in metastatic testicular cancer. Eur Urol 44 (2003) 233-244
3. Oldenburg J., Alfsen G.C., Lien H.H., Aas N., Waehre H., and Fossa S.D. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21 (2003) 3310-3317
4. Heidenreich A., Seger M., Schrader A.J., Hofmann R., Engelmann U., and Beyer J. Surgical considerations in residual tumor resection following chemotherapy for advanced testicular cancer. Eur Urol Suppl 3 2 (2004) 161 (abstract no. 632)
5. Hendry W.F., Norman A.R., Dearnaley D.P., et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. Cancer 94 (2002) 1668-1676
6. Heidenreich A., Ohlmann C., Hegele A., and Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 47 (2005) 64-71
7. Vergouwe Y., Steyerberg E.W., Foster R.S., Habbema J.D.F., and Donohue J.P. Validation of a prediction model and its predictors for the histology of residual masses in nonseminonatous testicular cancer. J Urol 165 (2001) 84-88
8. Vergouwe Y., Steyerberg E.W., de Wit R., et al. External validation of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 88 (2003) 843-847
9. Albers P., Weissbach L., Krege S., et al., German Testicular Cancer Study Group. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171 (2004) 1835-1838
10. Vergouwe Y., Steyerberg E.W., Foster R.S., et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicenter validation with more than 1000 patients. Eur Urol. 51 (2007) 424-432
11. Baltaci S., Orhan D., Türkölmez K., et al. p53, Bcl-2, and Bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. Br J Urol 87 (2001) 661-666